Meeting
2018 ASCO Annual Meeting
Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).
Authors
Yuankai Shi
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Yuankai Shi , Hang Su , Yongping Song , Wenqi Jiang , Xiuhua Sun , Wenbin Qian , Wei Zhang , Yuhuan Gao , Zhengming Jin , Jianfeng Zhou , Chuan Jin , Liqun Zou , Lugui Qiu , Wei Li , Jianmin Yang , Ming Hou , Shan Zeng , Peng Liu , Hui Zhou , Xiao Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03114683
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7536)
DOI
10.1200/JCO.2018.36.15_suppl.7536
Abstract #
7536
Poster Bd #
173
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
First Author: Hang Su
Poster
2022 ASCO Annual Meeting
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
First Author: Qin Xu
Poster
2020 ASCO Virtual Scientific Program
Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
First Author: Hang Su
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon